On January 7, 2026 Ottimo Pharma ("Ottimo"), an innovative, clinical-stage biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies to extend the lives of patients living with cancer, reported the US Food and Drug Administration clearance of the investigational new drug (IND) application for its lead candidate OTP-01. The first patient has been dosed and recruitment is well underway. All manufacturing of OTP-01 is occurring solely in the US.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"I am proud of our Ottimo team for their remarkable speed in bringing OTP-01 into the clinic since coming out of stealth," said David Epstein, Chair and Chief Executive Officer of Ottimo Pharma. "We are developing this unique, first-in-class antibody to be the ideal backbone therapy to combine with Antibody Drug Conjugates or chemotherapy, with the aim of creating a new standard of care across a wide range of solid tumors."
The broad Phase I/IIA, open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity of OTP-01. The study is enrolling patients in the US and Australia and will expand to approximately 20 centers globally.
"Our aim is to fully assess the potential of this distinctive antibody by generating comprehensive clinical and translational data to inform both dose selection and combination strategies, and to set the stage for broad development across multiple tumor types," said Dr. Mehdi Shahidi, Head of Development and Chief Medical Officer of Ottimo.
About OTP-01
OTP-01 is a first-in-class, investigational Fc-null, IgG1 monoclonal antibody featuring a unique dual-paratopic design that enables simultaneous engagement of the PD-1 immune checkpoint and the VEGFR-2 angiogenic pathway. As a single agent, OTP-01 maintains conventional IgG architecture, supporting optimal manufacturability and stability. Preclinical data supports the potential of OTP-01 to provide potent PD-1 inhibition combined with uniquely engineered allosteric VEGFR2 receptor inhibition (targeting ligands A/C/D) and modulates multiple immune subsets while optimally promoting tumor vascular normalization. This integrated dual-target engagement is designed to drive tumor microenvironment-biased distribution and enhance intratumoral immune activation. In addition, pre-clinical studies have demonstrated significantly improved anti-tumor efficacy and intratumoral CD8+ T cell infiltration compared to PD-1 inhibition alone. As a one-of-a-kind, next-generation investigative therapy for solid tumors, OTP-01 aims to offer a wider therapeutic window for patients, with the potential to improve outcomes across multiple indications. The antibody is produced with high manufacturing efficiency in the U.S.
(Press release, Ottimo Pharma, JAN 7, 2026, View Source [SID1234661807])